AZD5363

AZD5363 Basic information
Product Name:AZD5363
Synonyms:AZD5356;AZD5363;4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide;4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-;4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide AZD5363;AZD 5363 dihydrochloride;AZD5363;AZD-5363;AZD 5363;(S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidi
CAS:1143532-39-1
MF:C21H25ClN6O2
MW:428.92
EINECS:
Product Categories:Inhibitors;Akt;PI3K/Akt/mTOR;mTOR;PI3K
Mol File:1143532-39-1.mol
AZD5363 Structure
AZD5363 Chemical Properties
Melting point 161-164°C
density 1.381
storage temp. Refrigerator
solubility DMSO (Slightly), Methanol (Slightly)
pka13.93±0.50(Predicted)
form Solid
color Off-White to Pale Beige
Safety Information
MSDS Information
AZD5363 Usage And Synthesis
UsesAZD5363 is used in inhibiting the proliferation of certain tumor cell lines.
Biological Activityazd5363 is a novel, potent phosphoinositide 3-kinase (pi3k)/akt pathway inhibitor with ic50 value of ~200nm. [1]azd5363 is proved to inhibit castrate resistant prostate cancer (crpc) progression. clusterin (clu) and autophagy will be induced which may work as cytoprotective responses which can affect the downstream pi3k/akt signaling. [2] azd5363 inhibits the growth of a lot of human tumor cells in a dose dependent manner. the mode of action could be monotherapy as well as in combination with her2 inhibitors in breast cancer models. [3] it is suggested to induce cell apoptosis by measuring the expression of parp cleavage, the activity of caspase 3, et al. [1]most importantly, azd5363 can target the pi3k/akt-pathway in vivo significantly, thus reducing the serum psa-levels and tumor volume, finally, it could postpone the progression to crpc.[1]
targetAkt
storageStore at -20°C
references[1] thomas c, crafter c, davies b, zoubeidi a, gleave me. azd5363, a novel akt inhibitor, delays prostate cancer progression. the journal of urology. may 2011. 185(4s): e292-293.
[2] kumano m, zhang f, shiota m, crafter c, davies b, zoubeidi a, gleave m. clusterin knockdown enhances antitumor activity of a novel akt inhibitor, azd5363, through inhibition of autophagy in prostate cancer. the journal of urology. may 21 2012. e392.
[3] davies br, greenwood h, dudley p, et al. preclinical pharmacology of azd5363, an inhibitor of akt: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. mol. cancer ther. arp 2012. 11: 873.
AZD5363 Preparation Products And Raw materials
Rapamycin 2-Amino-5-chlorobenzophenone 2-amino-4-chlorobenzamide Trametinib GDC-0068 MK-2206 2HCl 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol Everolimus

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.